Dr. Mehran Nowfar-Rad, MD

Dr. Nowfar-Rad practices at Optum Surgery Center - Long Beach in Long Beach, California.

Dr. Nowfar-Rad's NPI, 1912979048, was assigned on February 2, 2006. Dr. Nowfar-Rad graduated from Keck School of Medicine of USC in 1997. Dr. Nowfar-Rad holds California license A66360.

Dr. Nowfar-Rad's primary practice is Optum Surgery Center - Long Beach, at 2600 Redondo Avenue, Long Beach, CA 90806. The practice phone is (562) 988-7147.

Dr. Nowfar-Rad's primary practice is Optum Surgery Center - Long Beach in Long Beach, California. The medical group on file is Optum - Downtown Los Angeles. Dmand AI also links Dr. Nowfar-Rad to 1 more physician office, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Nowfar-Rad practices, 3 sites in all. Vendor and product names are available with a free account.

Dermatopathology is Dr. Nowfar-Rad's primary specialty in the NPI Registry, under taxonomy code 207ND0900X. Dr. Nowfar-Rad is board certified in dermatology by the American Board of Dermatology. Dr. Nowfar-Rad is licensed in California.

Dmand AI lists contact dermatitis, rash, scalp rash, skin cyst and skin discoloration among the conditions Dr. Nowfar-Rad treats.

CMS data shows 32 Medicare services from Dr. Nowfar-Rad across 2 procedure codes in 2024, for 24 Medicare patients. Medicare paid $2,150 for them. Every service was in an office.

CMS counts 24 Medicare patients who saw Dr. Nowfar-Rad in 2024. The largest group is 65 to 74, with 13 patients. 71% of them have high blood pressure, and 67% have high cholesterol. Their average risk score is 0.76, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Nowfar-Rad's median patient age at 65, with 45% women.

In 2024, Dr. Nowfar-Rad wrote 364 Medicare Part D claims for 152 patients. 96% of them were for generic drugs. CMS names the drug for 291 of them, across 10 drugs with 11 or more claims each, at $4,334 in total drug cost. In 2023, CMS named 467 claims across 15 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 81 out of 100 for Dr. Nowfar-Rad for performance year 2024, reported as part of a group. Dr. Nowfar-Rad accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 76 procedures of skin biopsy by Dr. Nowfar-Rad, more than 73% of the clinicians it reports for that procedure.

Dmand AI links 2 papers to Dr. Nowfar-Rad.

CMS Open Payments shows 63 general payments to Dr. Nowfar-Rad from 22 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 100% of the total. Sanofi and Genzyme US Companies paid the most, $314.

Dr. Nowfar-Rad graduated from Keck School of Medicine of USC in 1997.

Dr. Nowfar-Rad is in network with 7 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Humana. Medicare plans come from the most carriers, 6. Check the plan with the practice before a visit.